Recent Advances in Novel Biologics in
the Management of Psoriatic Arthritis: Elevating the Standard of
A continuing medical education
activity provided by NAMCP and AAMCN
This activity is an archive from the live session from the 2021 Fall
Managed Care Forum.
If you participated in the live session, you are not eligible for
education credits from this archive.
This activity is valid from January 1, 2022, to March 1, 2023.
Instructions for CME/NCPD: Complete the pre-test, listen to the
audio and view the slides, complete the post test, complete the
evaluation form and hit submit. You will be asked to enter your name
and email address on the pre-test, evaluation and post-test. If you
close your internet browser without completing the post test, you
will have ONE more opportunity to complete. A score of 70% must be
achieved on the post test to receive continuing education credits.
If you do not pass the post test after two attempts, you will not be
eligible to try again. Once you complete the evaluation form and
score 70% or higher on your post test, you will automatically be
given your certificate.
To print or save your certificate, you will need to click on the
“download” button and either print or save.
This activity is intended for healthcare professionals practicing in
managed care environments.
This activity is supported by an
educational grant from
Novartis Pharmaceuticals Corporation
Psoriatic arthritis is a debilitating disease that may affect up to
1 million adults in the United States, affecting men and women
equally. Psoriatic arthritis is a progressive, inflammatory disease
that is associated with a number of dermatologic and musculoskeletal
manifestations. Patients can experience extreme pain and joint
damage that may affect their quality of life, physical function, and
ability to work. Symptoms include fatigue, joint inflammation, and
potentially progressive joint damage. This activity will examine the
considerations for assessment, diagnosis, treatment and management
of psoriatic arthritis.
Upon completion of this
activity, participants will be able to:
Discuss the current guidelines and
new clinical evidence to reach treat-to-target goals for
patients with psoriatic arthritis (PsA)
Explore novel targeted therapies for
active PsA based on mechanism of action, efficacy across PsA
domains, safety, and durability
Assess common comorbidities and
other challenges associated with PsA and strategies for
identifying and overcoming these challenges
Discuss the appropriate coordination
of care with a multidisciplinary team that includes
||Gary Owens, MD
Gary Owens Associates
has served as a consultant for Eli Lilly, ICON, Sanofi/Regeneron,
Magnolia Innovation, MCRA, Noctrix Octave Biosciences,
Vertex, and Xcenda. His presentation has been reviewed
for any bias.
MD has no financial relationships with ineligible
companies to disclose.
Jeremy Williams has no financial relationships with
ineligible companies to disclose.
Jacqueline Cole, RN, MS, CMCN has no financial
relationships with ineligible companies to disclose.
NAMCP and/or the presenter
has copyright or has received permissions for use of
materials provided in this activity.
Accreditation & Designation
This activity has been planned and implemented in accordance with
the accreditation requirements and policies of the Accreditation
Council for Continuing Medical Education (ACCME) through the joint
providership of the National Association of Managed Care Physicians
(NAMCP) and American Association of Managed Care Nurses (AAMCN). The
National Association of Managed Care Physicians is accredited by the
ACCME to provide continuing medical education for physicians.
NAMCP designates this enduring material for a maximum of 1 AMA
PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their
participation in the activity.
The American Association of Managed Care Nurses is accredited as a
provider of nursing continuing professional development by the
American Nurses Credentialing Center's Commission on Accreditation.
Nurses who complete this activity and achieve a passing score will
receive 1 hour in nursing continuing professional development.
This activity has been approved by the American Board of Managed
Care Nursing for 1.0 contact hours toward CMCN recertification
This activity is supported by an educational grant from
Novartis Pharmaceuticals Corporation
NAMCP and/or this website does not
provide medical advice, diagnosis or treatment. NAMCP does not
endorse or imply endorsement of the content on any linked website.
This website is to be used as an informational resource. With any
health related concern, consult with your physician or healthcare
Click Here To Continue